Vor Biopharma (VOR) Price & Analysis

Compare

894 Followers

VOR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.13 - $3.29

Previous CloseN/A

Volume424.02K

Average Volume (3M)32.03M

Market Cap

$272.41M

Enterprise Value$60.31M

Total Cash (Recent Filing)$60.03M

Total Debt (Recent Filing)$30.78M

Price to Earnings (P/E)―

Beta4.24

Next Earnings

Aug 07, 2025

EPS Estimate

-0.44

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding124,959,520

10 Day Avg. Volume4,341,799

30 Day Avg. Volume32,030,133

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.22

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-67.01

Enterprise Value/Ebitda-0.50

Forecast

1Y Price Target

$1.18

Price Target Upside-45.87% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Strategic PartnershipsVor announced an exclusive license agreement with RemeGen Co., Ltd to develop and commercialize telitacicept in ex-Greater China geographies.

Therapy PotentialAnalyst is bullish on telitacicept’s potential as a therapy for generalized myasthenia gravis in the U.S. and the EU.

Bears Say

Stock DowngradeDespite having a healthy balance sheet, the uncertainties due to potential strategic alternatives have led to a downgrade of VOR stock to Neutral from Buy.

Strategic UncertaintyThe decision to downgrade VOR is due to uncertainties regarding the company's pipeline development and business strategies going forward.

Workforce ReductionThe company is winding down all clinical and manufacturing operations, retaining only eight essential employees, leading to a workforce reduction of approximately 95%.

Vor Biopharma News

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Regencell Bioscience Holdings Ltd...

1d ago

FAZ

RGC

Vor Bio appoints Murray as Chief Commercial Officer

Vor Bio (VOR) announced the appointment of Dallan Murray as Chief Commercial Officer, effective immediately. Murray joins Vor...

3d ago

VOR

SRPT

Vor Bio appoints Cumbo, Detheux to board of directors

Vor Bio (VOR) announced the appointment of Alexander Cumbo and Michel Detheux, Ph.D., to its Board of Directors,...

17d ago

VOR

ITOS

Vor Bio appoints Zuraw as Chief Development Officer

Vor Bio (VOR) announced the appointment of Qing Zuraw, M.D., M.P.H., M.B.A., as Chief Development Officer, effective immediately....

21d ago

VOR

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Microbot Medical (MBOT) 82.20%...

23d ago

VOR

Vor Bio appoints Sandy Mahatme as CFO, CBO

Vor Bio (VOR) announced the appointment of Sandy Mahatme as CFO and chief business officer, effective July 9....

28d ago

VOR

Vor Biopharma Announces Key Leadership Changes

An update from Vor Biopharma ( ($VOR) ) is now available. On July 17, 2025, Vor Biopharma announced...

16d ago

VOR

Vor Biopharma Appoints New CFO to Drive Growth

Vor Biopharma ( ($VOR) ) just unveiled an update. On July 9, 2025, Vor Biopharma appointed Sandesh Mahatme...

28d ago

VOR

Unusually active option classes on open July 1st

Unusual total active option classes on open include: Veeva (VEEV), Las Vegas Sands (LVS), New Fortress Energy (NFE),...

1M ago

LVS

NFE

3 Penny Stocks to Watch Now, 7/1/25

Professional Diversity, Klotho Neurosciences, and Vor Biopharma are the 3 Penny Stocks to watch on July 1, 2025, based on TipRanks’...

1M ago

VOR

IPDN

Vor Biopharma’s Strategic Licensing and Growth Potential Justifies Buy Rating

In a report released today, Swayampakula Ramakanth from H.C. Wainwright upgraded Vor Biopharma (VOR – Research Report) to...

1M ago

VOR

Vor Bio upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright upgraded Vor Bio (VOR) to Buy from Neutral with a $3 price target Vor’s board has...

1M ago

VOR

Unusually active option classes on open June 27th

Unusual total active option classes on open include: 3D Systems (DDD), Vor Biopharma (VOR), INmune Bio (INMB), B...

1M ago

DDD

Vor Bio price target raised to $1 from 25c at Baird

Baird raised the firm’s price target on Vor Bio (VOR) to $1 from 25c and keeps a Neutral...

1M ago

VOR

VOR FAQ

What was Vor Biopharma, Inc.’s price range in the past 12 months?

Vor Biopharma, Inc. lowest stock price was $0.13 and its highest was $3.29 in the past 12 months.

What is Vor Biopharma, Inc.’s market cap?

Vor Biopharma, Inc.’s market cap is $272.41M.

When is Vor Biopharma, Inc.’s upcoming earnings report date?

Vor Biopharma, Inc.’s upcoming earnings report date is Aug 07, 2025 which is today.

How were Vor Biopharma, Inc.’s earnings last quarter?

Currently, no data Available

Is Vor Biopharma, Inc. overvalued?

According to Wall Street analysts Vor Biopharma, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Vor Biopharma, Inc. pay dividends?

Vor Biopharma, Inc. does not currently pay dividends.

What is Vor Biopharma, Inc.’s EPS estimate?

Vor Biopharma, Inc.’s EPS estimate is -0.44.

How many shares outstanding does Vor Biopharma, Inc. have?

Vor Biopharma, Inc. has 124,959,520 shares outstanding.

What happened to Vor Biopharma, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Vor Biopharma, Inc.?

Currently, no hedge funds are holding shares in VOR

Vor Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-125.43%

Trailing 12-Months

Asset Growth

-34.56%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Vor Biopharma, Inc.

Vor Biopharma (VOR) is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat cancer. The company is pioneering the development of engineered hematopoietic stem cells (eHSCs) to enable targeted cancer therapies while reducing off-target toxicity. Vor Biopharma aims to transform the treatment landscape for patients with hematologic malignancies by utilizing its proprietary technology to enhance the therapeutic index of anticancer agents.

Vor Biopharma (VOR) Earnings & Revenues

Historic Earnings Reports

VOR Stock 12 Month Forecast

Average Price Target

$1.18

▼(-45.87% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.23,0.4430769230769231,0.6561538461538462,0.8692307692307693,1.0823076923076924,1.2953846153846154,1.5084615384615385,1.7215384615384615,1.9346153846153846,2.147692307692308,2.3607692307692307,2.5738461538461537,2.786923076923077,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.23,0.3030769230769231,0.37615384615384617,0.4492307692307692,0.5223076923076923,0.5953846153846153,0.6684615384615384,0.7415384615384615,0.8146153846153845,0.8876923076923076,0.9607692307692306,1.0338461538461539,1.106923076923077,{"y":1.18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.23,0.2353846153846154,0.24076923076923076,0.24615384615384617,0.25153846153846154,0.2569230769230769,0.2623076923076923,0.2676923076923077,0.27307692307692305,0.2784615384615384,0.28384615384615386,0.28923076923076924,0.2946153846153846,{"y":0.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.35,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.23,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >